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ABSTRACT 
Anthramycin (ANT) is a member of the pyrolobenzodiazepine family and is a 
potent cytotoxic agent. Previously, we reported the topical delivery of ANT from a 
range of solvents that may also act as skin penetration enhancers (SPEs).  The skin 
penetration and uptake was monitored for simple solutions of ANT in propylene 
glycol (PG), dipropylene glycol (DiPG), Transcutol P (TC), isopropyl myristate 
(IPM), propylene glycol monocaprylate (PGMC) and propylene glycol monolaurate 
(PGML). The amounts of PG, DiPG and TC that were taken up by, and that 
penetrated the skin were also measured, with a clear dependence of ANT penetration 
on the rate and extent of PG and TC permeation. The present work investigates ANT 
skin delivery from a range of binary and ternary systems to determine any potential 
improvement in skin uptake compared with earlier results for the neat solvents. 
Following miscibility and stability studies a total of eight formulations were taken 
forward for evaluation in human skin in vitro. Binary systems of PG and water did not 
result in any skin permeation of ANT. Combining PG with either PGMC or PGML 
did promote skin penetration of ANT but no significant improvement was evident 
compared with PG alone. More complex ternary systems based on PG, DiPG, PGMC, 
PGML and water also did not show significant improvements on ANT permeation, 
compared with single solvents. Total skin penetration and retention of ANT ranged 
from 1 – 6 % across all formulations studied. Where ANT was delivered to the 
receptor phase there were also high amounts of PG permeation with >50% and ~35% 
PG present for the binary systems and ternary vehicles respectively. These findings 
along with our previous paper confirm PG as a suitable solvent / SPE for ANT either 
alone or in combination with PGML or PGMC. The results also underline the 
necessity for empirical testing to determine whether or not a vehicle is acting as a SPE 
for a specific active in a topical formulation.  
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1. Introduction 
Pyrrolobenzodiazepines (PBDs) are sequence-selective minor groove DNA-
interacting agents that restrict cellular processes thus leading to apoptosis. The term 
PBD derives from the three ring system of benzene, diazepine and pyrrole in the 
chemical structure of these compounds (Hartley, 2011). The first PBD molecule to be 
isolated was anthramycin (ANT) and the compound (Figure 1) was subsequently 
shown to be a potent cytotoxic agent both in vitro (Tendler and Korman, 1963) and in 
vivo  (Grunberg et al., 1966).  Because of dose dependent cardiotoxicity when ANT 
was administered intraperitoneally the molecule was not investigated further as a drug  
(Cargill et al., 1974). However, the possibility of reduced cardiotoxicity of ANT 
following topical application has never been investigated.  
Because of the potent antitumour activity of ANT, PBDs have been of 
considerable interest to several research groups and sibiromycin, tomaymycin, and 
neothramycin were later isolated from natural sources. Currently,  the PBD group 
comprises of these naturally occurring PBDs, synthetic PBD monomers, PBD 
conjugates and PBD dimers (Hartley, 2011). About eighty PBD monomers were 
synthesised by C2-aryl substitution and a number showed promising results when 
tested in the National Cancer Institute (NCI) 60 cancer cell line screening model. In 
order to increase DNA binding affinity and sequence selectivity, PBD conjugates 
were subsequently synthesised (Hartley, 2011). A number of C8-linked PBD-
conjugates showed enhanced DNA binding affinity and cytotoxic potencies compared 
to the monomers.  To date, the PBD dimer, SJG-136 (or SG 2000) (Gregson et al., 
2001) is the most widely evaluated PBD and shows superior DNA binding affinity 
compared with other PBDs as well as minor groove inter-and intrastrand cross-linking 
and mono-alkylation ability (Rahman et al., 2009). This PBD dimer also showed 
significant in vitro cytotoxic potency and in vivo antitumour activity (Alley et al., 
2004; Hartley et al., 2004), reached Phase II clinical trials in leukaemia and ovarian 
cancer (Mantaj et al., 2017) and is still being evaluated in a canine lymphoma clinical 
trial (Mellinas-Gomez et al., 2009).  More recently, PBD-type molecules have been 
attached to antibodies via chemical linkers to form Antibody-Drug Conjugates 
(ADCs), and several of these are at various stages of clinical trials, with two in Phase 
III (Mantaj et al., 2017).   
As promising results have been reported for SJG-136 in systemic 
chemotherapy trials (Janjigian et al., 2010) we hypothesised that PBDs might be 
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useful in the management of actinic keratoses and non-melanoma skin cancers (Haque 
et al., 2017). There is a clear need for non-invasive and tissue salvaging approaches 
for management of these conditions yet few topical therapies are currently available 
(Madal et al., 2010; Haque et al., 2015). To this end we investigated whether ANT, as 
a model PBD compound, could penetrate the skin and we also identified a number of 
solvents capable of promoting uptake of ANT into the skin (Haque et al., 2017). 
Finite dose permeation studies were performed using Franz cells with excised human 
skin. A range of vehicles was studied including 1,3-butanediol (BD), dipropylene 
glycol (DiPG), propylene glycol (PG), Transcutol P® (TC), isopropyl myristate 
(IPM), propylene glycol monolaurate (PGML) and propylene glycol monocaprylate 
(PGMC). As well as monitoring penetration of ANT the extent to which PG, TC, BD 
and DiPG permeated the skin was measured. ANT was delivered through the skin for 
PG, TC and PGML with the active “tracking” the skin penetration of both PG and TC. 
For PGMC, PGML and TC, skin uptake of ANT also correlated with the solvent 
uptake by the tissue. A number of previous publications from our group has also 
shown that combinations of solvents and/or skin penetration enhancers may have a 
synergistic effect on skin permeation of actives (Oliveira et al., 2012; Mohammed et 
al., 2014; Parisi et al., 2016).  The aims of the present work were therefore (i) to 
identify potential binary and ternary solvent systems for topical delivery of ANT and 
(ii) to probe any relationship between skin uptake of active and vehicle components.  
 
2. Materials and methods 
2.1 Materials 
ANT, sodium azide, Sudan III, PG, IPM, ethanol (EtOH) and acetone were 
supplied by Sigma Aldrich, UK. PGMC (Type II) and PGML (Type II) were kind 
donations from Gattefossé, St. Priest, France. DiPG and methylene blue were 
obtained from Acros Organics (UK). BD was purchased from Wako Pure Chemical 
Industries Ltd., Japan. Phosphate buffered saline (PBS) tablets were purchased from 
(Oxoid Limited, UK).  
 
2.2 Methods 
2.2.1 Miscibility, solubility parameter calculation, solubility and stability studies.   
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Miscibility studies of binary solvents were conducted at solvent ratios of 
10:90; 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20 and 90:10. For ternary 
miscibility determinations, the three solvents were added at different percentages, 
varying by 10%. Samples were mixed and where necessary, Sudan III and methylene 
blue were used to confirm miscibility. Tubes were left to stand for at least 24 h to test 
for phase separation. For ternary systems, phase diagrams were constructed using 
OriginPro® 8.0 software (OriginLab Cooperation, USA). Stability and solubility 
studies were conducted as reported previously at 32±0.5
°
C; stability was monitored up 
to 96 h and solubility was determined over 48 h (Haque et al., 2017). The 
concentration of ANT used in the stability studies ranged from 0.03 to 0.43 mg/mL 
depending on the binary or ternary system evaluated. Samples and solvents were 
analysed using the HPLC and GC methods described earlier (Haque et al., 2017). All 
analytical methods were validated according to ICH guidelines also as reported in this 
publication. 
 
Molecular Modelling Pro
®
 (ChemSW Inc., USA) software was used to 
calculate the van Krevelen Hoftyzer three dimensional solubility parameter (δ) values. 
For the binary and ternary solvents that were miscible, the solubility parameter (δm) 
was calculated using the following equations: 
 
δm (binary)=
𝛿1Ф1 + 𝛿2Ф2
Ф1+ Ф2
 …………………..Equation 1 
δm (ternary) =
𝛿1𝛷1+𝛿2𝛷2+𝛿3𝛷3
𝛷1+𝛷2+𝛷3
 …………...…Equation 2 
 
Where, Φ1, Φ2 and Φ3 are the respective mole fractions for solvents 1, 2 and 3; 
and δ1, δ2 and δ3 are their respective solubility parameters y (Breon et al., 1980).  
 
2.2.2 Finite dose permeation and mass balance studies of ANT and solvents from 
the mixed solvent systems 
Vertical glass Franz type diffusion cells were used for the ANT permeation 
studies in human skin as reported previously (Oliveira et al., 2012). Skin was obtained 
from the abdomen of donors who had undergone surgery following informed consent 
and ethical approval (Research Ethics Committee reference 07/H1306/98). The skin 
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was prepared by the heat separation method with samples comprising of stratum 
corneum and part of the viable epidermis (Kligman and Christophers, 1963). All skin 
samples were of the same thickness. The receptor phase was prepared by dissolving 
PBS tablets in 1 L of deionised water (pH 7.3 ±0.1) with the addition of 0.002% (w/v) 
sodium azide. Finite doses (~10 L/cm2) of saturated solutions of ANT in the various 
vehicles were applied in the donor chamber under non-occluded conditions and 
permeation of ANT and vehicles was monitored up to 48 h, as described in detail for 
the previous study (Haque et al., 2017). After the 48 h permeation study, the receptor 
medium was removed completely. The mass balance study was conducted and 
validated. The skin surface was washed twice with 1 ml of methanol and three times 
with 1 ml of methanol-water (50:50) mixture. The skin was removed from the Franz 
cell and placed in an Eppendorf® tube with 1 ml of methanol. All the tubes were 
placed in a rotor (rotating at 40 rpm) in a temperature-controlled oven (32 ± 0.5 °C) 
for 3 h. After extraction was completed, the tube was centrifuged at 13,000 rpm at 32 
°C for 15 min. Aliquots were taken from the supernatant portion and analysed by 
HPLC and GC in order to quantify the amounts of ANT and respective solvents on 
the surface of the skin and inside the skin. The washing and extraction methods were 
validated as reported previously (Haque et al., 2017).  
 
2.2.3 Statistical analysis 
The data were analysed in MS Excel® 2007 and the results presented as 
mean±SD. IBM SPSS Statistics software (version 22.0) was used for statistical 
evaluation. The Shapiro-Wilk test was used to check the normality of the results. If 
the p value calculated from the test was greater than 0.05, the data were assumed to be 
normally distributed (parametric) and one way analysis of variance (ANOVA) was 
conducted. Multiple comparisons between each individual group were performed by a 
post hoc Tukey test. For non-parametric data, a Kruskal-Wallis one way ANOVA 
followed by multiple comparisons between groups was performed. Equal variance 
was assumed in all cases. p<0.05 was considered as a statistical significant difference. 
 
3. Results and discussion 
3.1 Miscibility, stability, solubility parameter values and solubility  
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All hydrophilic solvents were miscible at all ratios in binary systems. PGMC 
and PGML were miscible with all candidate hydrophilic and hydrophobic solvents 
with the exception of water. IPM was miscible with TC, PGMC and PGML in all 
ratios and immiscible in PG, BD and water (W). IPM was miscible in DiPG only at 
ratios of 10:90 or 90:10. Subsequently, ternary systems comprising PG-TC-IPM, W-
TC-PGMC, W-TC-PGML, W-DiPG-PGMC and W-PG-PGMC systems were 
prepared based on miscible regions of their respective ternary phase diagrams (data 
not shown).  
Recovery values of ANT for binary systems are shown in Figure 2. ANT is 
not stable in TC (Haque et al., 2017) and rapid degradation occurred in PG:TC 
(50:50) with ~6.5% of the initial concentration present after 96 h. The recoveries of 
ANT at 96 h in EtOH:W (70:30), W:TC (50:50), W:DiPG (50:50) and PG:TC (80:20) 
were ~51.5, 54, 64.5 and 38%, respectively. The lower recoveries of ANT in these 
vehicles were accompanied by colour changes. The other solutions remained 
transparent throughout the experiment. With the exception of W:PG (20:80), where  
~88% of ANT was recovered, greater than 90% recovery of ANT was found for all 
other binary mixtures at 96 h. Eleven ternary solvent systems were evaluated for the 
stability of ANT (Figure 3). Good recovery of ANT (>90%) was found for 
W:PG:PGMC (10:80:10), PG:DiPG:PGMC (50:40:10) and PG:DiPG:PGML 
(50:40:10). ANT recovery was ~81.5% of the initial concentration for 
W:DiPG:PGMC (40:50:10). In PG:TC:IPM (40:50:10) the lowest recovery of ANT 
(3.69%) was evident. In the other ternary solvent systems less than 35% of ANT 
remained at 96 h. As for the binary systems, colour changes were evident for those 
ternary systems that demonstrated marked instability. Where the recovery of ANT 
was <80% at 96 h, binary and ternary systems were not evaluated further. ANT 
contains an amide group and it can also have an imine bond between the N10-C11 
positions in anhydroanthramycin, which is interconvertible with the carbinolamine 
form. In addition, oxidation is possible at the C9 position to generate an ortho quinone 
imine, a degradant that is cardiotoxic. 
The solubility parameters of the final candidate vehicles and corresponding 
ANT solubility values are shown in Table 1. Previously, the solubility parameter of 
ANT was calculated as 15.35 (cal/cm
3
)
1/2 
and high solubility of the molecule had been 
observed for solvents with comparable solubility parameters (Haque et al., 2017). 
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However, highest solubility for the binary mixtures, was observed with PG:PGMC 
and PG:PGML. These vehicles have comparatively lower solubility parameter values 
than the W:PG vehicle, that has the closest value to ANT. For the ternary systems, 
highest solubility is evident for W:PG:PGMC compared with PG:DiPG:PGMC and 
PG:DiPG:PGML. The solubility parameter value for W:PG:PGMC, 14.54 
(cal/cm
3
)
1/2
, is also the closest of all the values of the ternary systems to that for ANT.  
 
3.2 Finite dose permeation and mass balance studies for ANT 
Figure 4a shows the permeation profiles of ANT for binary and ternary solvent 
systems for finite dose applications under non-occluded conditions. For the eight 
vehicles, ANT permeation was only evident for PG:PGMC, PG:PGML, 
W:PG:PGMC and PG:DiPG:PGML. Cumulative amounts that permeated at 48 h were 
as follows: PG:PGML - 31.34 μg/cm2 , PG:PGMC -  13.20 μg/cm2, W:PG:PGMC – 
12.53 μg/cm and PG:DiPG:PG - 10.74 μg/cm2. The amounts of ANT that permeated 
from these mixtures were not significantly different (p>0.05) and are comparable to 
ANT permeation observed for single solvents (Haque et al.., 2017).  The percentage 
permeation profiles (Figure 4b) confirm the highest value for PG:PGML (2.63%) and 
the corresponding values for PG:PGMC, PG:DiPG:PGML and W:PG:PGMC were 
1.4, 1.2 and 0.9% respectively. For the neat solvents the highest percentage 
permeation was observed for PGML (13.16%) with ANT cumulative permeation of 
8.5 g/cm2 (Haque et al., 2017). The cumulative amounts of ANT permeated between 
PGML and PG:PGML (90:10) were found to be equal to the significance threshold 
(p=0.05). There was no significant increase in amount of ANT that permeated from 
PG:PGML (90:10) compared with neat PG (p>0.05). 
The mass balance results for ANT binary formulations are summarised in 
Table 2 and confirm that most of the applied dose was recovered from the surface of 
the skin. The percentages of ANT remaining in the skin for PG:PGML, W:PG 
(20:80), PG:PGMC and W:PG (50:50) were ~3.4, 1.3, 1.0 and 0.8%  respectively. 
Table 2 shows less than 80% of total recovery values of ANT from the surface, inside 
the human skin and from the receptor fluid for W:PG (50:50), W:PG (20:80) and 
PG:PGML (90:10). However, the stability results of ANT in these three systems were 
almost 88% and above. When the stability testing was conducted, ANT was kept only 
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with the respective solvent system. However, during the skin experiment studies, the 
drug solution was kept in contact with the viable epidermis for 48 hours. The extent of 
skin metabolism of ANT is not known. Therefore, skin metabolism of ANT may have 
contributed in the lower recovery values of ANT. As for the binary systems most of 
the applied amount of ANT was recovered from the skin surface for the ternary 
systems (Table 2). ANT skin retention was comparable for PG:DiPG:PGML  (3.01%) 
and W:PG:PGMC (1.93%).  PG:DiPG:PGML deposited  more ANT in skin compared 
with W:DiPG:PGMC and PG:DiPG:PGMC (p<0.05). For the PG:DiPG:PGML and 
W:PG:PGMC systems, the skin retention of ANT was also similar to that previously 
observed for neat PG (Haque et al., 2017). More than 80% of ANT was recovered in 
total for all ternary formulations.  
 
3.3 Finite dose permeation and mass balance studies of solvents for binary and ternary 
systems 
The permeation of PG was quantified for solutions of ANT in W:PG (50:50) 
and W:PG (20:80), PG:PGMC and PG:PGML (Table 3). Extraction and washing of 
the skin surface was also conducted to determine any residual PG in or on the skin. 
For W:PG (50:50) and (20:80), cumulative amounts of PG permeation were not 
significantly different at 48 h (17.12 and 24.55%, respectively, p>0.05). The 
cumulative percentage permeation of PG at 48 h when applied as a neat vehicle was 
reported as ~21.87% (Haque et al., 2017) and is not significantly different (p>0.05) 
from the data reported here for the PG binary systems. Overall recovery of PG from 
the W:PG vehicles did not exceed ~ 30%, also comparable to recovery of PG for the 
solution of ANT in neat PG (Table 3). Interestingly no ANT permeation was observed 
for these systems (Section 3.2) and this may reflect the rapid depletion and 
evaporation of PG following application of these binary systems to the skin. No PG 
could be quantified from the surface and inside the skin for W:PG (50:50).  For W:PG 
(20:80), 4.35±2.86 % and 2.20±0.88% of PG were recovered from the surface and 
extracted from the skin respectively. These values are comparable to the amounts 
recovered for the solution of ANT in neat PG (Table 3).  
For the PG:PGMC and PG:PGML systems, significantly higher (p<0.05) 
permeation of PG was observed compared with the W:PG systems, with values of 
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52.11 and 71.92%, respectively at 48 h. The addition of 10% of either ester also 
results in significantly increased (p<0.05) permeation of PG compared with neat PG 
(Table 3). However, PG could not be quantified on the surface and inside the skin for 
either system. Approximately 30% of the applied dose of PGML was retained inside 
the skin but PGMC could not be quantified in the skin, with most of the compound 
recovered from the skin surface. Total recovery for both PGMC and PGML was 
~100% (Table 3). The high permeation of PG from the PG/ester systems mirrors the 
superior ANT permeation from these mixtures, compared with the failure of other 
binary systems to delivery ANT where comparatively lower skin penetration of PG is 
evident (Section 3.2, Table 3).  
Mass balance results for PG and DiPG at 48 h for ANT solutions in the neat 
solvents and ternary systems across human skin are shown in Table 3. The amounts of 
PG that permeated from W:PG:PGMC, PG:DiPG:PGML  and PG:DiPG:PGMC were 
39.6%, 35.0% and 26.5%. As for the binary systems, the two ternary systems 
demonstrating comparatively higher PG permeation also achieved effective skin 
penetration of ANT.  However, there were no significant differences in the amounts 
of PG that permeated for the three ternary systems and no differences compared with 
neat PG (p>0.05). PG could not be quantified in the skin for any of the ternary 
systems. No PG was detected on the surface of the skin for W:PG:PGMC; for 
PG:DiPG:PGMC and PG:DiPG:PGML, ~9 and 5%, of PG respectively were 
recovered from the skin surface. The total recoveries of PG in all ternary systems 
were poor and this may reflect evaporation of PG from the formulation 
DiPG permeation was evaluated for W:DiPG:PGMC, PG:DiPG:PGMC and 
PG:DiPG:PGML. For PG:DiPG:PGML, a significantly higher percentage of DiPG 
permeation was evident (44.95%), compared with W:DiPG:PGMC and 
PG:DiPG:PGMC where the corresponding amounts that permeated were 17.13 and 
17.90%, respectively (p<0.05). The PG:DiPG:PGML system also enhanced 
permeation of DiPG to a significant extent  (p<0.05) compared with neat DiPG. As 
for PG, high DiPG permeation from the PG:DiPG:PGML vehicle is consistent with 
ANT skin permeation, in contrast to the other two DPG mixtures where no ANT was 
detected in the receptor phase (Section 3.2).  DiPG skin retention was highest (8.32%) 
for PG:DiPG:PGML. For W:DiPG:PGMC and PG:DiPG:PGMC similar retention 
values (3.93 and 3.50%, respectively) and permeation (17.13 and  17.90%) of DiPG 
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were evident. Thus, the total absorption values of DiPG in PG:DiPG:PGML 
(50:40:10) were higher (53.27%) than the other two ternary systems. The total 
recovery of DiPG was >85%. No PGMC was measured in the skin nor in the receptor 
phase for any of the PGMC ternary systems. The total recovery of PGMC in the three 
systems ranged from 68 to 81%. For PG:DiPG:PGML, 19.05% of PGML was 
retained in the skin and 40.67% was recovered from the skin surface (Table 3).  
 
4. Conclusions 
Previous work had confirmed the dependence of ANT skin permeation on the 
corresponding penetration of specific solvents/skin penetration enhancers. Although 
more complex systems were evaluated in the present work, it is evident that 
significant skin uptake and the presence of vehicle components in the receptor phase 
is critical for effective percutaneous delivery of the active. Binary W:PG systems did 
not result in any ANT skin penetration.  In contrast, combinations of PG with PG-
fatty acid esters did promote delivery of ANT, although PG is present in high amounts 
(90%). The ANT permeation from these vehicles is also associated with significant 
amounts of PG in the receptor phase (>50%). In addition, only those ternary systems 
containing PG resulted in skin penetration of ANT, consistent with results from the 
earlier work with neat PG. When PGMC is selected as the ester in the ternary system, 
high amounts of PG are required (80%) for penetration of the active, compared with 
the corresponding systems with PGML where the PG content is 50%. The overall 
delivery observed for the binary and ternary systems is still comparable to that for 
neat solvents, suggesting that the best formulation strategy should be based on a 
single solvent or skin penetration enhancer and specifically, PG.  
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List of Tables 
Table 1. Solubility parameters for binary and ternary systems and corresponding 
solubility values of ANT* at 32±0.5
°
C (n=3, mean±SD). 
Solvent mixtures Solubility Parameter 
[(cal/cm
3
)
1/2
] 
Solubility 
(mg/ml) 
W:PG (50:50) 18.52 47.09±4.06 
W:PG (20:80) 15.85 117.15±3.96 
PG:PGMC (90:10) 13.65 128.29±19.86 
PG:PGML (90:10) 13.61 123.08±16.20 
W:PG:PGMC (10:80:10) 14.54 145.07±9.22 
W:DiPG:PGMC (40:50:10) 16.27 80.59±2.10 
PG:DiPG:PGMC (50:40:10) 12.90 115.80±21.06 
PG:DiPG:PGML (50:40:10) 12.86 82.40±18.07 
*Solubility parameter for ANT - 15.35 (cal/cm
3
)
1/2
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Table 2. Percent recovery of the applied dose of ANT from binary and ternary 
systems after 48 h permeation studies (n≥3, mean±SD). 
Solvent(s)  % of the applied dose recovered 
Skn surface In skin Receptor phase Total 
PG 80.12±3.15 1.31±0.74 0.64±0.07 82.06±3.76 
DiPG 98.49±15.34 0.21±0.01 NQ 98.71±15.34 
PGMC 73.79±16.79 17.50±8.16 NQ 91.29±21.22 
PGML 75.10±21.35 4.01±0.99 13.14±0.41 92.25±22.15 
W:PG (50:50) 68.02±1.91 0.76±0.14 NQ 68.78±1.83 
W:PG (20:80) 71.92±6.95 1.32±1.06 NQ 73.24±7.06 
PG:PGMC (90:10) 79.00±22.85 1.04±0.85 1.43±1.29 81.47±22.09 
PG:PGML (90:10) 68.15±7.87 3.42 ±1.31 2.63±1.27 74.20±6.99 
W:PG:PGMC 
(10:80:10) 
98.77±7.34 1.93±0.71 0.85±0.51 101.55±7.80 
W:DiPG:PGMC 
(40:50:10) 
82.83±8.62 0.39±0.27 NQ 83.22±8.53 
PG:DiPG:PGMC 
(50:40:10) 
85.09±3.11 0.20±0.09 NQ 85.28±3.10 
PG:DiPG:PGML 
(50:40:10) 
76.86±1.89 3.01±1.12 1.22±0.56 81.09±3.13 
* NQ= not quantified. 
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Table 3. Percent recovery of the applied dose of solvent(s) from binary and ternary 
systems after 48 h permeation studies (n≥3, mean±SD). 
Solvent(s) Vehicle 
Dose 
applied 
(mg) 
% of the applied dose recovered 
Skin 
surface 
In skin Receptor phase Total 
PG  10.36 6.86±2.01 2.14±1.44 21.87±10.27 30.87±13.68 
DiPG  10.20 98.86±4.08 2.11±0.48 7.98±2.27 108.95±3.03 
PGMC  9.50 96.63±8.86 7.45±0.40 ND 104.08±8.86 
PGML  9.31 95.88±6.12 4.17±1.26 ND 100.06±6.19 
W:PG (50:50) PG 5.18 NQ NQ 17.12±1.02 17.12±1.02 
W:PG (20:80) PG 8.29 4.35±2.86 2.20±0.88 24.55±7.93 31.10±7.10 
PG:PGMC 
(90:10) 
PG 9.32 NQ NQ 52.11±13.93 52.11±13.93 
PGMC 0.95 99.59±2.81 NQ ND 99.59±2.81 
PG:PGML 
(90:10) 
PG 9.32 NQ NQ 71.92±8.40 71.92±8.40 
PGML 0.93 70.60±7.57 29.04±1.82 ND 99.65±7.03 
W:PG:PGMC 
(10:80:10) 
PG 8.29 NQ NQ 39.61±6.03 39.61±6.03 
PGMC 0.95 67.89±3.84 NQ ND 67.89±3.84 
W:DiPG:PGM
C (40:50:10) 
DiPG 5.1 81.04±2.02 3.93±1.10 17.13±4.29 102.11±5.12 
PGMC 0.95 81.35±1.33 ND ND 81.35±1.33 
PG:DiPG:PGM
C (50:40:10) 
PG 5.18 9.12±6.92 NQ 26.54±4.52 35.66±7.95 
DiPG 4.08 67.32±7.09 3.50±0.90 17.90±3.36 88.73±6.60 
PGMC 0.95 81.35±3.03 NQ ND 81.35±3.03 
PG:DiPG:PGM
L (50:40:10) 
PG 5.18 5.07±2.41 NQ 35.01±5.81 40.08±4.92 
DiPG 4.08 
51.44±23.5
2 
8.32±2.27 44.95±20.41 104.71±8.37 
PGML 0.93 40.67±1.47 19.05±0.17 ND 59.72±1.61 
*ND= Not detected and NQ= not quantified.  
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Figure 1. Anthramcyin 
Figure 2. Percentages of the applied ANT recovered in binary mixtures at 24, 48, 72 
and 96 h at 32±0.5
°
C (n=3, mean±SD). 
Figure 3. Percentages of the applied ANT recovered in ternary mixtures at 24, 48, 72 
and 96 h at 32±0.5
°C (n≥3, mean±SD). 
Figure 4. Plot of (a) cumulative amount of ANT and (b) percentage of applied dose of 
ANT permeated as a function of time through human skin in binary and ternary 
solvent systems (n≥3, mean±SD). 
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